CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-12 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −19 | $375.65 | $7K | 29,743 |
| 2026-01-12 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −15 | $377.82 | $6K | 29,728 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −39 | $353.95 | $14K | 25,025 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −42 | $355.16 | $15K | 24,983 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −41 | $356.09 | $15K | 24,942 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −96 | $357.17 | $34K | 24,846 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −123 | $358.18 | $44K | 24,723 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −85 | $359.14 | $31K | 24,638 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −155 | $360.22 | $56K | 24,483 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −98 | $361.45 | $35K | 24,385 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −73 | $362.38 | $26K | 24,312 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −47 | $363.55 | $17K | 24,265 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −199 | $364.83 | $73K | 24,066 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −220 | $365.56 | $80K | 23,846 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −50 | $366.41 | $18K | 23,796 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −41 | $367.40 | $15K | 23,755 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −92 | $368.62 | $34K | 23,663 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −40 | $369.48 | $15K | 23,623 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −19 | $370.87 | $7K | 23,604 |
| 2026-01-12 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale 10b5-1 | −2 | $372.46 | $745 | 23,602 |
Page 15 of 41 · 816 trades